RU2010113994A - Применение панкреатического полипептида человека в качестве терапевтического средства - Google Patents
Применение панкреатического полипептида человека в качестве терапевтического средства Download PDFInfo
- Publication number
- RU2010113994A RU2010113994A RU2010113994/15A RU2010113994A RU2010113994A RU 2010113994 A RU2010113994 A RU 2010113994A RU 2010113994/15 A RU2010113994/15 A RU 2010113994/15A RU 2010113994 A RU2010113994 A RU 2010113994A RU 2010113994 A RU2010113994 A RU 2010113994A
- Authority
- RU
- Russia
- Prior art keywords
- ala
- pro
- tyr
- arg
- diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/1526—Amino acids; Peptides; Protein hydrolysates; Nucleic acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2006—IL-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/04—Amoebicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
1. Применение пептида Ala-Pro-Leu-Glu-Pro-Val-Tyr-Pro-Gly-Asp-Asn-Ala-Thr-Pro-Glu-Gln-Met-Ala-Gln-Tyr-Ala-Ala-Asp-Leu-Arg-Arg-Tyr-Ile-Asn-Met-Leu-Thr-Arg-Pro-Arg-Tyr-NH2 для получения фармацевтической композиции для лечения и/или профилактики злокачественной опухоли, аутоиммунных заболеваний, фиброзов, воспалительных заболеваний, нейродегенеративных заболеваний, инфекционных заболеваний, заболеваний легких, заболеваний сердца и сосудов и болезней обмена веществ. ! 2. Применение пептида по п.1, где злокачественная опухоль, аутоиммунное заболевание, фиброз, воспалительное заболевание, нейродегенеративное заболевание, инфекционное заболевание, заболевание легких, заболевание сердца и сосудов или болезнь обмена веществ выбраны из СПИД, ассоциированных со СПИД заболеваний, ВИЧ, астмы, синдрома Оменна, идиопатического фиброза легких и атопических нарушений у генетически восприимчивых индивидуумов. ! 3. Применение пептида по п.1 или 2 для получения состава для перорального введения новорожденным, детям ясельного возраста и/или детям дошкольного возраста. ! 4. Применение пептида по п.1 или 2 для получения лиофилизированного состава или буферного жидкого состава. ! 5. Фармацевтическая композиция, содержащая пептид Ala-Pro-Leu-Glu-Pro-Val-Tyr-Pro-Gly-Asp-Asn-Ala-Thr-Pro-Glu-Gln-Met-Ala-Gln-Tyr-Ala-Ala-Asp-Leu-Arg-Arg-Tyr-Ile-Asn-Met-Leu-Thr-Arg-Pro-Arg-Tyr-NH2, по меньшей мере, совместно с одним фармацевтически приемлемым носителем, криопротектором, лиопротектором, эксципиентом и/или разбавителем. ! 6. Фармацевтическая композиция по п.5 в форме лиофилизата или жидкого буферного раствора. ! 7. Фармацевтическая композиция по п.5 или 6, пригодная для внутривенного введения, перорального введения или для введения посредством ингаляции. ! 8. Фармацевтич
Claims (9)
1. Применение пептида Ala-Pro-Leu-Glu-Pro-Val-Tyr-Pro-Gly-Asp-Asn-Ala-Thr-Pro-Glu-Gln-Met-Ala-Gln-Tyr-Ala-Ala-Asp-Leu-Arg-Arg-Tyr-Ile-Asn-Met-Leu-Thr-Arg-Pro-Arg-Tyr-NH2 для получения фармацевтической композиции для лечения и/или профилактики злокачественной опухоли, аутоиммунных заболеваний, фиброзов, воспалительных заболеваний, нейродегенеративных заболеваний, инфекционных заболеваний, заболеваний легких, заболеваний сердца и сосудов и болезней обмена веществ.
2. Применение пептида по п.1, где злокачественная опухоль, аутоиммунное заболевание, фиброз, воспалительное заболевание, нейродегенеративное заболевание, инфекционное заболевание, заболевание легких, заболевание сердца и сосудов или болезнь обмена веществ выбраны из СПИД, ассоциированных со СПИД заболеваний, ВИЧ, астмы, синдрома Оменна, идиопатического фиброза легких и атопических нарушений у генетически восприимчивых индивидуумов.
3. Применение пептида по п.1 или 2 для получения состава для перорального введения новорожденным, детям ясельного возраста и/или детям дошкольного возраста.
4. Применение пептида по п.1 или 2 для получения лиофилизированного состава или буферного жидкого состава.
5. Фармацевтическая композиция, содержащая пептид Ala-Pro-Leu-Glu-Pro-Val-Tyr-Pro-Gly-Asp-Asn-Ala-Thr-Pro-Glu-Gln-Met-Ala-Gln-Tyr-Ala-Ala-Asp-Leu-Arg-Arg-Tyr-Ile-Asn-Met-Leu-Thr-Arg-Pro-Arg-Tyr-NH2, по меньшей мере, совместно с одним фармацевтически приемлемым носителем, криопротектором, лиопротектором, эксципиентом и/или разбавителем.
6. Фармацевтическая композиция по п.5 в форме лиофилизата или жидкого буферного раствора.
7. Фармацевтическая композиция по п.5 или 6, пригодная для внутривенного введения, перорального введения или для введения посредством ингаляции.
8. Фармацевтическая композиция по п.5 или 6 в форме состава искусственного материнского молока или заменителя материнского молока, пригодная для пероральной доставки новорожденным, детям ясельного возраста и/или детям дошкольного возраста.
9. Фармацевтическая композиция по п.5 или 6, пригодная для лечения и/или профилактики злокачественной опухоли, аутоиммунного заболевания, фиброза, воспалительного заболевания, нейродегенеративного заболевания, инфекционного заболевания, заболевания легких, заболевания сердца и сосудов или болезней обмена веществ.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07017749 | 2007-09-11 | ||
EP07017749.8 | 2007-09-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2010113994A true RU2010113994A (ru) | 2011-10-20 |
Family
ID=40260870
Family Applications (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2010113962/15A RU2010113962A (ru) | 2007-09-11 | 2008-09-09 | Применение фертирелина и дельта-эндорфина в качестве терапевтических средств |
RU2010114019/15A RU2010114019A (ru) | 2007-09-11 | 2008-09-09 | Минигастрин в качестве терапевтического средства |
RU2010114032/15A RU2010114032A (ru) | 2007-09-11 | 2008-09-09 | Применение салусина бета индивидуально или в комбинации с октреотидом в качестве терапевтического средства |
RU2010113994/15A RU2010113994A (ru) | 2007-09-11 | 2008-09-09 | Применение панкреатического полипептида человека в качестве терапевтического средства |
RU2010114052/15A RU2010114052A (ru) | 2007-09-11 | 2008-09-09 | Применение пептида в качестве терапевтического средства |
RU2010114050/15A RU2010114050A (ru) | 2007-09-11 | 2008-09-09 | Применение пептида рецептора il-1 индивидуально или в комбинации с октадециловым эфиром d-ala-gln в качестве терапевтического средства |
RU2010114053/15A RU2010114053A (ru) | 2007-09-11 | 2008-09-09 | Применение лептина (22-56) в качестве терапевтического средства |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2010113962/15A RU2010113962A (ru) | 2007-09-11 | 2008-09-09 | Применение фертирелина и дельта-эндорфина в качестве терапевтических средств |
RU2010114019/15A RU2010114019A (ru) | 2007-09-11 | 2008-09-09 | Минигастрин в качестве терапевтического средства |
RU2010114032/15A RU2010114032A (ru) | 2007-09-11 | 2008-09-09 | Применение салусина бета индивидуально или в комбинации с октреотидом в качестве терапевтического средства |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2010114052/15A RU2010114052A (ru) | 2007-09-11 | 2008-09-09 | Применение пептида в качестве терапевтического средства |
RU2010114050/15A RU2010114050A (ru) | 2007-09-11 | 2008-09-09 | Применение пептида рецептора il-1 индивидуально или в комбинации с октадециловым эфиром d-ala-gln в качестве терапевтического средства |
RU2010114053/15A RU2010114053A (ru) | 2007-09-11 | 2008-09-09 | Применение лептина (22-56) в качестве терапевтического средства |
Country Status (8)
Country | Link |
---|---|
US (7) | US20100210562A1 (ru) |
EP (7) | EP2190464A2 (ru) |
JP (7) | JP2010539015A (ru) |
KR (7) | KR20100056522A (ru) |
AU (7) | AU2008297895A1 (ru) |
CA (7) | CA2698966A1 (ru) |
RU (7) | RU2010113962A (ru) |
WO (19) | WO2009040033A2 (ru) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2010324527A1 (en) * | 2009-11-24 | 2012-07-19 | Commonwealth Scientific And Industrial Research Organisation | Methods, kits and reagents for diagnosing, aiding diagnosis and/or monitoring progression of a neurological disorder |
US9993516B2 (en) | 2013-11-19 | 2018-06-12 | The Brigham And Women's Hospital, Inc. | Treatment of left ventricular non-compaction and dilated cardiomyopathy by inhibiting melanocortin receptor four |
EP3570866B1 (en) | 2017-01-20 | 2023-05-10 | ISR Immune System Regulation Holding AB (publ) | Novel use of known compounds- intracellular infections |
US11434258B2 (en) | 2017-01-20 | 2022-09-06 | ISR Immune System Regulation Holding AB | Compounds (immunorhelins) |
AU2018209239B2 (en) | 2017-01-20 | 2023-02-02 | ISR Immune System Regulation Holding AB (publ) | Novel compounds (immunorhelins- intracellular infections) |
JP2020508306A (ja) | 2017-02-22 | 2020-03-19 | イミューン システム レギュレェイション ホールディング エービー | アジュバント免疫療法剤として使用するためのゴナドトロピン放出ホルモン |
CN108578682B (zh) * | 2018-07-13 | 2022-04-12 | 浙江省医学科学院 | 艾塞那肽在制备用于治疗肺纤维化的药物中的应用 |
WO2021222354A2 (en) * | 2020-04-28 | 2021-11-04 | Nova Southeastern University | Compositions including alamandine peptides and methods for treatment of pulmonary disease using alamandine peptides |
WO2023237661A1 (en) * | 2022-06-09 | 2023-12-14 | Institut National de la Santé et de la Recherche Médicale | Use of endothelin receptor type b agonists for the treatment of aortic valve stenosis |
Family Cites Families (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4097471A (en) * | 1977-05-26 | 1978-06-27 | American Home Products Corporation | Polypeptides with morphine-like activity |
FR2537131B1 (fr) * | 1980-04-17 | 1986-05-09 | Roques Bernard | Nouveaux derives d'acides amines et leur application therapeutique |
DE3274798D1 (en) * | 1981-10-05 | 1987-02-05 | Nicholas P Plotnikoff | Process for using endorphins as antitumour agents |
US4537878A (en) * | 1981-10-05 | 1985-08-27 | Tni Pharmaceuticals, Inc. | Process for using endogenous enkephalins and endorphins to stimulate the immune system |
JPS6016934A (ja) * | 1983-07-06 | 1985-01-28 | Kaneshiro Nagai | 抗腫瘍剤 |
JPS61186322A (ja) * | 1985-02-13 | 1986-08-20 | Nippon Univ | 免疾調節剤 |
EP0222578A3 (en) * | 1985-11-06 | 1990-04-04 | Merck & Co. Inc. | Use of cyclic somatostatin analogues in the treatment of immediate hypersensitivity diseases |
NZ226557A (en) * | 1987-10-15 | 1990-07-26 | Syntex Inc | Pharmaceutical compositions for the intranasal administration of a biologically active polypeptide in powder form and process for their preparation |
US5231166A (en) * | 1988-10-25 | 1993-07-27 | Takeda Chemical Industries, Ltd. | Endothelin |
DE69116772T2 (de) * | 1990-09-03 | 1996-07-25 | Kuraray Co | Peptid oder seine Salze |
US5434136A (en) * | 1990-12-14 | 1995-07-18 | Mathias; John R. | Treatment of motility disorders with a GNRH analog |
DK0527283T3 (da) | 1991-08-12 | 1998-08-10 | Nestle Sa | Levnedsmiddelsammensætning |
MX9301789A (es) * | 1992-04-03 | 1993-10-01 | Iaf Biochem Int | Nuevos oligopeptidos lipofilicos con actividad inmunomoduladora. |
US5792451A (en) * | 1994-03-02 | 1998-08-11 | Emisphere Technologies, Inc. | Oral drug delivery compositions and methods |
WO1995029193A2 (en) * | 1994-04-22 | 1995-11-02 | The Government Of The United States Of America Represented By The Secretary, Department Of Health And Human Services | Melanoma antigens |
DE69524214T3 (de) | 1994-05-06 | 2008-05-15 | Pfizer Inc. | Azithromycin enthaltende arzneiverabreichungsformen mit gesteuerter wirkstoffabgabe |
EP0885016B1 (en) | 1996-02-19 | 2003-04-16 | Amersham Health AS | Thermally stabilized contrast agent |
TW360501B (en) | 1996-06-27 | 1999-06-11 | Nestle Sa | Dietetically balanced milk product |
US5932547A (en) * | 1996-07-03 | 1999-08-03 | Alza Corporation | Non-aqueous polar aprotic peptide formulations |
DK0832565T3 (da) | 1996-09-24 | 2000-11-20 | Nestle Sa | Mælkeerstatningsprodukt og fremgangsmåde til fremstilling deraf |
US5830434A (en) * | 1997-02-26 | 1998-11-03 | Medical University Of South Carolina Foundation For Research Development | Methods of treating non-insulin dependent diabetes mellitus with pancreatic polypeptide |
WO1999003491A1 (en) * | 1997-07-15 | 1999-01-28 | Novo Nordisk A/S | New use of nociceptin |
US6242421B1 (en) * | 1997-11-06 | 2001-06-05 | Richard Lloyd Bowen | Methods for preventing and treating Alzheimer's disease |
IL138214A0 (en) * | 1998-03-09 | 2001-10-31 | Zealand Pharmaceuticals As | Pharmacolgically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
WO2000030461A1 (fr) | 1998-11-24 | 2000-06-02 | Societe Des Produits Nestle S.A. | Procede de preparation d'une composition proteique et d'une formule infantile la contenant |
US6313370B1 (en) * | 1999-04-29 | 2001-11-06 | Morton Hyson | Medicated wrap |
JP2003519667A (ja) * | 2000-01-10 | 2003-06-24 | アミリン・ファーマシューティカルズ,インコーポレイテッド | トリグリセリドレベルの調節および脂質異常血症の治療のためのエキセンジンおよびそのアゴニストの使用 |
US20020013331A1 (en) * | 2000-06-26 | 2002-01-31 | Williams Robert O. | Methods and compositions for treating pain of the mucous membrane |
US20020072495A1 (en) * | 2000-09-21 | 2002-06-13 | Oleg Chertov | LL-37 is an immunostimulant |
NZ525830A (en) * | 2000-10-13 | 2005-07-29 | Norwood Immunology Ltd | Disease prevention by reactivation of the thymus |
AU2002316221A1 (en) * | 2001-05-16 | 2002-11-25 | Nicholas P. Plotnikoff | Methods for inducing sustained immune response |
WO2003015820A1 (fr) * | 2001-08-10 | 2003-02-27 | Takeda Chemical Industries, Ltd. | Medicaments combines d'agoniste de la gnrh |
US20030082225A1 (en) * | 2001-10-19 | 2003-05-01 | Mason Paul Arthur | Sterile, breathable patch for treating wound pain |
ES2287065T3 (es) | 2001-11-23 | 2007-12-16 | Societe Des Produits Nestle S.A. | Proceso para la preparacion de leche en polvo y productos lacteos concentrados. |
EP1466610A4 (en) * | 2001-11-26 | 2007-03-21 | Daiichi Asubio Pharma Co Ltd | MEDICAL COMPOSITIONS FOR NASAL ABSORPTION |
US8410053B2 (en) * | 2001-11-26 | 2013-04-02 | Trustees Of Tufts College | Methods for treating autoimmune disorders, and reagents related thereto |
EP1358888A1 (en) * | 2002-02-28 | 2003-11-05 | Robert Bals | The human peptide antibiotic LL-37/hCAP-18 is an inducer of angiogenesis |
CN1249240C (zh) * | 2002-06-25 | 2006-04-05 | 中国人民解放军军事医学科学院基础医学研究所 | 表达载体pBVTB及其构建方法和在HCV疫苗研究中的应用 |
GB0223655D0 (en) * | 2002-10-10 | 2002-11-20 | Mabtech Ab | Method of diagnosis |
EP1583541B1 (en) * | 2002-11-20 | 2011-01-12 | NeuroNova AB | Compounds and methods for increasing neurogenesis |
WO2004052390A1 (en) * | 2002-12-11 | 2004-06-24 | Amylin Pharmaceuticals, Inc. | Methods and compositions for treating polycystic ovary syndrome |
US7777000B2 (en) * | 2003-03-06 | 2010-08-17 | The Regents Of The University Of California | Anti-viral activity of cathelicidin peptides |
WO2005041873A2 (en) * | 2003-10-24 | 2005-05-12 | Azopax Therapeutics Llc | Formulation of exendin-4 |
WO2005040195A2 (en) * | 2003-10-24 | 2005-05-06 | Azopax Therapeutics Llc | Formulation of exendins |
CA2546843C (en) * | 2003-11-20 | 2015-01-06 | Neuronova Ab | Compounds and methods for increasing neurogenesis |
EP1541168B1 (en) * | 2003-12-09 | 2010-11-24 | Intervet International BV | Method of synchronising ovulation in cattle |
JP4426575B2 (ja) * | 2004-04-02 | 2010-03-03 | 独立行政法人科学技術振興機構 | 心機能抑制性/降圧性新規内因性生理活性ペプチド |
JP2008515437A (ja) * | 2004-10-08 | 2008-05-15 | フォーブス メディ−テック(リサーチ) インコーポレーテッド | 血管活性腸管ポリペプチド医薬品 |
US7704955B2 (en) * | 2004-11-24 | 2010-04-27 | Neopro Pain, Inc. | Methods and compositions for modulating conditions in both mammals and plants |
EP1827481A2 (en) * | 2004-12-15 | 2007-09-05 | Aditech Pharma AB | A composition comprising pp for the treatment of gastrointestinal disorders |
US7550150B2 (en) * | 2005-03-15 | 2009-06-23 | Barros Research Institute | Methods of treating or preventing a disease, disorder or condition associated with a viral infection |
US20060269617A1 (en) * | 2005-05-26 | 2006-11-30 | Suracell, Inc. | Supplement compositions and method of use for enhancement of insulin sensitivity |
EP1888034A2 (en) * | 2005-05-26 | 2008-02-20 | Yissum Research Development Company, of The Hebrew University of Jerusalem | Compositions and methods using same for delivering agents into a target organ protected by a blood barrier |
JP2008543869A (ja) * | 2005-06-17 | 2008-12-04 | マンカインド コーポレイション | 癌腫のための多価同調・増幅免疫療法 |
US20090175795A1 (en) * | 2005-07-29 | 2009-07-09 | Amprotein Corporation | Chimeric therapeutic agents |
ATE458491T1 (de) * | 2005-08-26 | 2010-03-15 | Univ Leland Stanford Junior | Verfahren zur behandlung von kopfschmerzen durch verabreichung von oxytocin |
JP2009507050A (ja) * | 2005-09-08 | 2009-02-19 | ガストロテック・ファルマ・アクティーゼルスカブ | 胆道ジスキネジーおよび/または胆道痛/不快の治療のためのglp−1分子の使用 |
US20070142287A1 (en) * | 2005-12-20 | 2007-06-21 | Biomed Solutions, Llc | Compositions And Methods For Treatment Of Cancer |
WO2007076162A2 (en) * | 2005-12-29 | 2007-07-05 | Kansas State University Research Foundation | Antimicrobial cathelicidin peptides |
JP2009523128A (ja) * | 2006-01-04 | 2009-06-18 | ドゥ−コープ テクノロジーズ リミテッド | 殺菌組成物及びそれを使用する方法 |
US20070197445A1 (en) * | 2006-01-18 | 2007-08-23 | University Of Cincinnati | Compounds for control of appetite |
GB0601179D0 (en) * | 2006-01-20 | 2006-03-01 | Univ Cambridge Tech | Therapies for psychotic disorders |
JP5678359B2 (ja) | 2006-03-10 | 2015-03-04 | ラボスイス アーゲー | 物質を可溶化、分散、および安定化させる方法とその方法により製造される生成物とその使用 |
WO2008052043A2 (en) * | 2006-10-24 | 2008-05-02 | Cogenesys, Inc. | Opioid receptor agonist fusion proteins |
EP2150271A1 (en) * | 2007-05-11 | 2010-02-10 | The Texas A & M Univsersity System | Hormone normalization therapy and uses thereof |
WO2008143151A1 (ja) * | 2007-05-11 | 2008-11-27 | Proteinexpress Co., Ltd. | サリューシンをターゲットとする動脈硬化性疾患の治療剤及び検出薬 |
CA2696833A1 (en) * | 2007-07-15 | 2009-01-22 | Yitzchak Hillman | Disease treatment via antimicrobial peptides or their inhibitors |
-
2008
- 2008-09-09 RU RU2010113962/15A patent/RU2010113962A/ru not_active Application Discontinuation
- 2008-09-09 JP JP2010523388A patent/JP2010539015A/ja active Pending
- 2008-09-09 WO PCT/EP2008/007742 patent/WO2009040033A2/en active Application Filing
- 2008-09-09 AU AU2008297895A patent/AU2008297895A1/en not_active Abandoned
- 2008-09-09 WO PCT/EP2008/007484 patent/WO2009033684A1/en active Application Filing
- 2008-09-09 WO PCT/EP2008/008030 patent/WO2009046864A2/en active Application Filing
- 2008-09-09 CA CA2698966A patent/CA2698966A1/en not_active Abandoned
- 2008-09-09 JP JP2010523416A patent/JP2010539043A/ja active Pending
- 2008-09-09 WO PCT/EP2008/007941 patent/WO2009040070A2/en active Application Filing
- 2008-09-09 AU AU2008306192A patent/AU2008306192A1/en not_active Abandoned
- 2008-09-09 WO PCT/EP2008/008132 patent/WO2009033804A2/en active Application Filing
- 2008-09-09 WO PCT/EP2008/007930 patent/WO2009046846A2/en active Application Filing
- 2008-09-09 JP JP2010523384A patent/JP2010539011A/ja active Pending
- 2008-09-09 KR KR1020107005655A patent/KR20100056522A/ko not_active Application Discontinuation
- 2008-09-09 CA CA2699255A patent/CA2699255A1/en not_active Abandoned
- 2008-09-09 AU AU2008309996A patent/AU2008309996A1/en not_active Abandoned
- 2008-09-09 EP EP08802240A patent/EP2190464A2/en not_active Withdrawn
- 2008-09-09 KR KR1020107005623A patent/KR20100061481A/ko not_active Application Discontinuation
- 2008-09-09 CA CA2698992A patent/CA2698992A1/en not_active Abandoned
- 2008-09-09 WO PCT/EP2008/007708 patent/WO2009043480A2/en active Application Filing
- 2008-09-09 JP JP2010523406A patent/JP2010539033A/ja active Pending
- 2008-09-09 WO PCT/EP2008/007597 patent/WO2009033721A2/en active Application Filing
- 2008-09-09 WO PCT/EP2008/007707 patent/WO2009043479A2/en active Application Filing
- 2008-09-09 CA CA2698822A patent/CA2698822A1/en not_active Abandoned
- 2008-09-09 EP EP08802044A patent/EP2187936A1/en not_active Withdrawn
- 2008-09-09 WO PCT/EP2008/007872 patent/WO2009033763A1/en active Application Filing
- 2008-09-09 AU AU2008297954A patent/AU2008297954A1/en not_active Abandoned
- 2008-09-09 KR KR1020107005606A patent/KR20100064367A/ko not_active Application Discontinuation
- 2008-09-09 JP JP2010523361A patent/JP2010538988A/ja active Pending
- 2008-09-09 RU RU2010114019/15A patent/RU2010114019A/ru not_active Application Discontinuation
- 2008-09-09 KR KR1020107005646A patent/KR20100056520A/ko not_active Application Discontinuation
- 2008-09-09 KR KR1020107005648A patent/KR20100075438A/ko not_active Application Discontinuation
- 2008-09-09 JP JP2010523430A patent/JP2010539057A/ja active Pending
- 2008-09-09 WO PCT/EP2008/007850 patent/WO2009033754A2/en active Application Filing
- 2008-09-09 WO PCT/EP2008/007798 patent/WO2009033750A2/en active Application Filing
- 2008-09-09 US US12/677,295 patent/US20100210562A1/en not_active Abandoned
- 2008-09-09 JP JP2010523354A patent/JP2010538983A/ja active Pending
- 2008-09-09 CA CA2699087A patent/CA2699087A1/en not_active Abandoned
- 2008-09-09 RU RU2010114032/15A patent/RU2010114032A/ru not_active Application Discontinuation
- 2008-09-09 WO PCT/EP2008/007865 patent/WO2009033759A2/en active Application Filing
- 2008-09-09 RU RU2010113994/15A patent/RU2010113994A/ru not_active Application Discontinuation
- 2008-09-09 CA CA2699222A patent/CA2699222A1/en not_active Abandoned
- 2008-09-09 EP EP08802368A patent/EP2190452A2/en not_active Withdrawn
- 2008-09-09 EP EP08802157A patent/EP2197462A2/en not_active Withdrawn
- 2008-09-09 KR KR1020107005607A patent/KR20100059857A/ko not_active Application Discontinuation
- 2008-09-09 US US12/677,572 patent/US20100210536A1/en not_active Abandoned
- 2008-09-09 AU AU2008306245A patent/AU2008306245A1/en not_active Abandoned
- 2008-09-09 US US12/677,583 patent/US20100210556A1/en not_active Abandoned
- 2008-09-09 WO PCT/EP2008/007640 patent/WO2009043460A1/en active Application Filing
- 2008-09-09 WO PCT/EP2008/007607 patent/WO2009043440A2/en active Application Filing
- 2008-09-09 WO PCT/EP2008/007712 patent/WO2009040018A2/en active Application Filing
- 2008-09-09 RU RU2010114052/15A patent/RU2010114052A/ru not_active Application Discontinuation
- 2008-09-09 EP EP08802011A patent/EP2187934A1/en not_active Withdrawn
- 2008-09-09 US US12/677,743 patent/US20100184677A1/en not_active Abandoned
- 2008-09-09 RU RU2010114050/15A patent/RU2010114050A/ru not_active Application Discontinuation
- 2008-09-09 US US12/676,900 patent/US20100173845A1/en not_active Abandoned
- 2008-09-09 US US12/677,294 patent/US20100273701A1/en not_active Abandoned
- 2008-09-09 KR KR1020107005577A patent/KR20100061475A/ko not_active Application Discontinuation
- 2008-09-09 WO PCT/EP2008/007450 patent/WO2009033663A1/en active Application Filing
- 2008-09-09 AU AU2008297933A patent/AU2008297933A1/en not_active Abandoned
- 2008-09-09 US US12/677,312 patent/US20100210558A1/en not_active Abandoned
- 2008-09-09 CA CA2699114A patent/CA2699114A1/en not_active Abandoned
- 2008-09-09 EP EP08802148A patent/EP2188015A2/en not_active Withdrawn
- 2008-09-09 WO PCT/EP2008/007869 patent/WO2009033761A2/en active Application Filing
- 2008-09-09 AU AU2008297529A patent/AU2008297529A1/en not_active Abandoned
- 2008-09-09 RU RU2010114053/15A patent/RU2010114053A/ru not_active Application Discontinuation
- 2008-09-09 WO PCT/EP2008/008004 patent/WO2009040085A2/en active Application Filing
- 2008-09-09 EP EP08802520A patent/EP2274053A2/en not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2010113972A (ru) | Применение cnp-22 отдельно или в сочетании с физалемином в качестве терапевтического средства | |
RU2010113986A (ru) | Применение пептида в качестве терапевтического средства | |
RU2010114049A (ru) | Cgrp в качестве терапевтического средства | |
RU2010114044A (ru) | Применение белка полосы 3 (824-829) и/или фактора ингибирования высвобождения меланотропина в качестве терапевтического средства при лечении инфекции pseudomonas aeruginosa | |
RU2010113974A (ru) | Применение противовоспалительного пептида-1 в качестве терапевтического средства | |
RU2010113983A (ru) | Применение туфтсина в качестве терапевтического средства | |
RU2010113994A (ru) | Применение панкреатического полипептида человека в качестве терапевтического средства | |
RU2010114054A (ru) | Применение пептида в качестве терапевтического средства | |
RU2010114000A (ru) | Применение нейропептида sf индивидуально или в сочетании с glp-2 в качестве терапевтического средства | |
RU2010114031A (ru) | Проадреномедуллин индивидуально или в сочетании с большим гастрином i в качестве терапевтического средства | |
RU2010114002A (ru) | Применение фактора ингибирования высвобождения меланотропина в качестве терапевтического средства при лечении инфекции pseudomonas aeruginosa | |
RU2010114030A (ru) | Применение пептида в качестве терапевтического средства | |
RU2010113998A (ru) | Применение пептида rfmwmr в качестве терапевтического средства | |
RU2010114014A (ru) | Применение глюкагона (1-29) отдельно или в сочетании с нейропептидом w30 в качестве терапевтического средства | |
RU2010114051A (ru) | Применение grf-1(1-29) и кортиколиберина в качестве терапевтических средств | |
RU2010113989A (ru) | Применение пептида в качестве терапевтического средства | |
RU2010114039A (ru) | Применение октреотида в качестве терапевтического средства | |
RU2010114062A (ru) | ПРИМЕНЕНИЕ ПЕПТИДА Pro-Gly-Thr-Cys-Glu-Ile-Cys-Ala-Tyr-Ala-Ala-Cys-Thr-Gly-Cys В КАЧЕСТВЕ ТЕРАПЕВТИЧЕСКОГО СРЕДСТВА | |
RU2010114035A (ru) | Применение rfrp индивидуально или в комбинации с нейрокинином в в качестве терапевтического средства | |
RU2010114005A (ru) | Применение сочетания пептидов тимозина бета4 и индуцирующего дельта-сон пептида в качестве терапевтического средства | |
RU2010114037A (ru) | Применение белка полосы 3 и расар-27 в качестве терапевтического средства | |
RU2010114060A (ru) | Применение пептида в качестве терапевтического средства |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20110912 |